
CFO Eli Lilly on his acquisition spree: ‘We’re betting’ on future revenue
Eli Lilly (LLY) beat sales expectations on Thursday and raised its outlook on strong performance from its drugs GLP-1, Mounjaro and Zepbound. Despite this strength, revenue from its new diet pill, Foundayo, fell well short of the Street’s expectations. Foundayo, launched in the United States in April, generated just $184 million in sales in the three months ended…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Gn bussni